8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT


                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


                          Date of Report: July 17, 2006
                        (date of earliest event reported)


                                ATS MEDICAL, INC.
             (Exact name of registrant as specified in its charter)


                         Commission File Number: 0-18602
                           ---------------------------


         Minnesota                                       41-1595629
(State or other jurisdiction                   (IRS Employer Identification No.)
     of incorporation)

                      3905 Annapolis Lane North, Suite 105
                          Minneapolis, Minnesota 55447
                    (Address of Principal Executive Offices)


                                 (763) 553-7736
              (Registrant's telephone number, including area code)


                                 Not Applicable
          (Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


================================================================================






ITEM 2.02  RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

         On July 17, 2006, ATS Medical, Inc. (the "Company") issued a press
release to report preliminary revenue expectations for the second quarter ended
June 30, 2006. The full text of the press release is furnished as Exhibit 99.1
hereto and is incorporated by reference. The information in this current report,
including the exhibit thereto, is not deemed "filed" for purposes of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.


ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS.

(c)      Exhibits

         99.1 Press Release dated July 17, 2006, of ATS Medical, Inc.








                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                             ATS MEDICAL, INC.




                                             By:  /s/ Michael D. Dale
                                                  ------------------------------
                                                  Michael D. Dale
                                                  Chief Executive Officer

Date:  July 17, 2006






                                  EXHIBIT INDEX


Exhibit No.                           Description
- ----------        --------------------------------------------------------------

   99.1           Press Release, dated July 17, 2006, of ATS Medical, Inc.

EX-99.1

EXHIBIT 99.1




[ATS MEDICAL LOGO]

                                 Contact:   Michael Dale, President/CEO
                                            763/553-7736

                               Investors:   EVC Group, Inc.
                                            Jennifer Beugelmans, 646/277-8704
                                            Doug Sherk, 415/896-6820
                                            Steve DiMattia, 646/277-8706 (Media)


FOR IMMEDIATE RELEASE


 ATS MEDICAL PROVIDES UPDATE ON 3F THERAPEUTICS ACQUISITION AND REVENUE OUTLOOK
                               FOR SECOND QUARTER
              Record Year-Over-Year Revenue Growth in all Markets

MINNEAPOLIS, July 17, 2006 -- ATS Medical, Inc. (NASDAQ: ATSI) today provided an
update on its pending acquisition of 3F Therapeutics as well as preliminary
revenue expectations for the second quarter ended June 30, 2006.

"Given the recent extension of the terms of our definitive agreement to acquire
3F Therapeutics, we wanted to provide an update on the transaction and the
expected timing for its close," said Michael Dale, President and CEO of ATS
Medical. "Specific to sales results, we look forward to reporting strong second
quarter revenue growth in all markets, fueled by sales increases in all of our
product lines. We will issue our final results for the second quarter of 2006
and conduct a conference call after market close on Wednesday, August 2, 2006.
Mr. Dale continued, "We believe these results underscore the cardiac surgery
community's continued embrace of our products and our mission to establish ATS
Medical as a leading provider of proprietary technology to the cardiovascular
surgeon. Based upon our performance during the first six months of 2006, we are
reiterating our guidance to surpass $40 million in revenue for the full year."

"Regarding the acquisition of 3F Therapeutics, as previously disclosed, we are
in the process of restating our financial statements to reflect separate
accounting for embedded derivatives in our convertible senior notes issued in
October 2005," continued Mr. Dale. "We expect to file amendments to our latest
Form 10-K and Form 10-Q with the SEC early this week reflecting these new
financials, which will allow us to file an amendment to our Form S-4 related to
the 3F Therapeutics acquisition and respond to the SEC's last round of comments.
We are optimistic we




can conclude the SEC review process in time to hold our shareholder meeting and
close this transaction in the latter half of August 2006."

ABOUT ATS MEDICAL
- -----------------
ATS Medical, Inc. manufactures and markets products and services focused on
cardiac surgery. The Company, global in scope, has been headquartered in
Minneapolis since its founding in 1991. More than 100,000 ATS Open Pivot(R)
Heart Valves, which utilize a unique pivot design resulting in exceptional
performance and low risk profile, have been implanted in patients worldwide. ATS
Medical's focus on serving the cardiac surgery community is further strengthened
by product and service offerings including ATS Simulus(TM) annuloplasty products
for heart valve repair, Surgi-Frost(R) and Frost-Byte(R) products for surgical
cryoablation of cardiac arrhythmias, RTI Cardiovascular for allograft tissue
services, QAS home monitoring services for anticoagulation therapy, and the
development of PARSUS blood filtration technology. The ATS Medical web site is
http://www.atsmedical.com.

SAFE HARBOR
- -----------
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company and
its management. Actual results could differ materially from those projected in
the forward looking statements as a result of a number of important factors,
including regulatory actions, competition, pricing pressures, supplier actions
and management of growth. For a discussion of these and other risks and
uncertainties that could affect the Company's activities and results, please
refer to the Company's filings with the Securities and Exchange Commission
including its Form 10-K for the year ended December 31, 2005, as amended.


                                       ###